The Klosterneuburg-based deeptech startup Sarcura has raised €7 million in a seed+ round to develop its next-generation cell therapy manufacturing platform. The round was co-led by Lansdowne Investment Company Cyprus and IST Cube.
- Founded in 2019 by Daniela Buchmayr, Erwin Gorjup, and Martin Fischlechner, Sarcura develops an instrument platform that combines silicon chip technology and microfluidic processing to scale global manufacturing capacity, enabling cost-effective and safe cell therapies for patients.
“Sarcura unites cutting-edge silicon technologies such as integrated photonics in microfluidic cartridges, to automate, miniaturize and bring real-time control to cell therapy manufacturing”,
says Daniela Buchmayr, co-founder and CEO of Sarcura.
- Besides leading investors, the round was also joined by HCVC, tecnet equity, and European family offices with industrial biopharmaceutical background, with participation of returning seed investors Axilium Holding, Novacapital, and Nina Capital.
- Sarcura will spend the new capital to boost the growth of the team and to develop its first prototype.
